Therapy for nonalcoholic fatty liver disease: current options and future directions
P Campbell, A Symonds, AS Barritt IV - Clinical therapeutics, 2021 - Elsevier
Purpose Nonalcoholic fatty liver disease (NAFLD) is a highly prevalent chronic liver disease
that is driven by the metabolic syndrome. NAFLD encompasses nonalcoholic fatty liver,> 5%
fat in the liver without inflammation of fibrosis, nonalcoholic steatohepatitis (NASH), fat plus
varying degrees of inflammation and fibrosis, and cirrhosis of the liver from NASH. As facets
of the metabolic syndrome, particularly diabetes and obesity, become more common
worldwide, the incidence of new NAFLD is increasing. Methods A qualitative systematic …
that is driven by the metabolic syndrome. NAFLD encompasses nonalcoholic fatty liver,> 5%
fat in the liver without inflammation of fibrosis, nonalcoholic steatohepatitis (NASH), fat plus
varying degrees of inflammation and fibrosis, and cirrhosis of the liver from NASH. As facets
of the metabolic syndrome, particularly diabetes and obesity, become more common
worldwide, the incidence of new NAFLD is increasing. Methods A qualitative systematic …